TELA Bio Outlines 2027 Expense Projections Following $17 Million Cost Reduction Plan
TELA Bio has provided a strategic financial outlook, projecting an expense range of $76 million to $78 million for the year 2027. This guidance follows the implementation of a comprehensive cost-reduction initiative aimed at trimming $17 million from the company's operating expenses. The announcement comes as the company enters a new leadership phase, with the CEO marking their first 90 days in office. The restructuring is designed to optimize the company's financial position and streamline operations as it moves toward long-term stability.
Tickers: $TELA
Topics: CEO transition earnings results quarterly performance
Read the full article at Seeking Alpha
Part of the story Skydance Outlines $6 Billion Cost-Cutting Plan Following Merger (2 articles)